Drug Profile
AVL 3288
Alternative Names: Anvylic-3288; AVL-3288; UCI-4083Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Anvyl Pharmaceuticals
- Developer Anvyl
- Class Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cognition disorders
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in USA (PO)
- 16 Sep 2017 University of Maryland plans a phase I trial for Cognition disorders (NCT03281694)
- 01 Nov 2016 New York State Psychiatric Institute and National Institute of Mental Health initiate a phase I trial for Cognition disorders associated with schizophrenia in USA (PO) (NCT02978599)